<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904809</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10410</org_study_id>
    <nct_id>NCT04904809</nct_id>
  </id_info>
  <brief_title>Perclose Multi-Access DUS Study</brief_title>
  <official_title>Perclose Multi-Access DUS Study: Assess the Safety and Performance of the Perclose ProGlide® Suture-Mediated Closure System and the Perclose Prostyle Suture-Mediated Closure and Repair System in Managing Multiple Venous Access Sites (Evaluation by Duplex Ultrasound)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety of multiple access site closure in a single vein with the&#xD;
      Perclose SMC by scheduled DUS at discharge and at 30 days (if complications observed at&#xD;
      discharge DUS) in asymptomatic or non-visible subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-arm, US multi-center, descriptive study to evaluate the&#xD;
      safety of multiple access site closure in a single vein with the ProGlide. A total of 35&#xD;
      subjects will be registered at 3 US investigational sites. All subjects must have femoral DUS&#xD;
      at discharge and at a 30-day follow-up visit (if vascular complications are observed at&#xD;
      discharge by either the investigator or the core laboratory).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular Complications at Discharge</measure>
    <time_frame>Generally within 24 hours of procedure.</time_frame>
    <description>Vascular complications detected by scheduled DUS at discharge asymptomatic/non-visible complication subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular Complications at 30 Days</measure>
    <time_frame>30 Days post procedure</time_frame>
    <description>Vascular complications detected by scheduled DUS at 30 days in asymptomatic/non-visible complication subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Reported Vascular Complications</measure>
    <time_frame>Procedure to 30 days Post Procedure</time_frame>
    <description>Any vascular complications will also be analyzed as the descriptive endpoints. Vascular complications include but are not limited to:&#xD;
Femoral vein stenosis (&gt; 50%) development at the puncture site related to closure technique&#xD;
Deep vein thrombosis in the target limb&#xD;
Venous bleeding, retroperitoneal bleeding&#xD;
Venous access site injury including vessel laceration&#xD;
Re-bleeding at the access site&#xD;
Hematoma&#xD;
Subcutaneous hematoma&#xD;
Pseudoaneurysm&#xD;
AV fistula&#xD;
Thrombus&#xD;
Non-flow limiting suture material&#xD;
Access site-related nerve injury&#xD;
Persisting for &gt; 30 days (major)&#xD;
Resolved ≤ 30 days&#xD;
Pulmonary embolism&#xD;
Requiring surgical or endovascular intervention and/or resulting in death, to be confirmed by CT pulmonary angiography, lung ventilation/perfusion scan (VQ scan), or autopsy (major)&#xD;
Not requiring or resulting above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of procedure</measure>
    <time_frame>Procedure</time_frame>
    <description>Cryo-ablation, RF ablation, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Femoral Vein Access Sites Per Subject</measure>
    <time_frame>Procedure</time_frame>
    <description>Number of Femoral Vein Access Sites Per Subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Femoral Vein Access Sites Per Leg</measure>
    <time_frame>Procedure</time_frame>
    <description>Number of Femoral Vein Access Sites Per Leg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheath Sizes Used</measure>
    <time_frame>Procedure</time_frame>
    <description>Sheath Sizes Used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Suture Mediated Closure (SMC) Systems used</measure>
    <time_frame>Procedure</time_frame>
    <description>Total Number of SMC used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Suture Mediated Closure (SMC) Systems used per closure procedure</measure>
    <time_frame>Procedure</time_frame>
    <description>Number of SMC used per closure procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Suture Mediated Closure (SMC) Systems used per access site</measure>
    <time_frame>Procedure</time_frame>
    <description>Number of SMC used per access site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success rate per access site</measure>
    <time_frame>Procedure</time_frame>
    <description>Successful hemostasis without surgical conversion, or additional non-study device (additional manual compression and subcutaneous stitch are regarded as the standard of care and not included failure)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>All Registered Pts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All registered patients will have multiple access sites in a single vein closed utilizing the ProGlide Suture Mediated Closure System and/or Prostyle Suture Mediated Closure and Repair System (when available).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Perclose ProGlide Suture Mediated Closure System</intervention_name>
    <description>The ProGlide and Prostyle SMC (when approved) in this study will be used for multiple access site closures in a single vein in the ablation procedure.</description>
    <arm_group_label>All Registered Pts</arm_group_label>
    <other_name>Perclose ProStyle Suture Medication Closure and Repair System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Subject is planned to have an EP procedure that requires multiple sheaths insertion in&#xD;
             a single femoral vein&#xD;
&#xD;
          -  All the access sites are planned to be treated with ProGlide/Prostyle SMC&#xD;
&#xD;
          -  Written informed consent is obtained prior to the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Visible thrombus (angiographic or ultrasound) prior to the ablation procedure&#xD;
&#xD;
          -  Prior ipsilateral deep vein thrombosis&#xD;
&#xD;
          -  Has active symptoms and/or a positive test result of COVID-19 or other rapidly&#xD;
             spreading novel infectious agent within the prior 2 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjaya K Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soroosh Kiani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hajime Kusano</last_name>
    <phone>1-408-845-1626</phone>
    <email>hajime.kusano@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stacy Scribner</last_name>
    <phone>6517565602</phone>
    <email>stacy.scribner@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Preiser</last_name>
      <email>tpreise@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Soroosh Kiani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margie Miller</last_name>
      <email>m2miller@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Sanjaya Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

